Mylan generic Accutane launch
Executive Summary
Mylan has "addressed all outstanding issues" with FDA over a generic isotretinoin launch and is "prepared to comply with all risk management program requirements before us," Senior VP Jim Mauzey says. "Our sales representatives are trained on the product, and our wholesalers and retail customer base has been contacted and presented with our program for introduction. We look forward to an approval." The ANDA has been held up by discussions regarding appropriate risk management for Accutane (1"The Pink Sheet" March 11, p. 16)...
You may also be interested in...
Generic Accutane risk management
FDA is still considering risk management requirements for generic versions of Roche's Accutane (isotretinoin), the agency says in an Aug. 12 response to a Roche citizen petition. "FDA has been unable to reach a decision on your petition because it raises significant issues requiring extensive review and analysis," the agency said. Mylan's isotretinoin ANDA has been held up by discussions on risk management, but the company told analysts July 25 that Mylan has "addressed all outstanding issues" with FDA and looks "forward to an approval" (1"The Pink Sheet" August 5, In Brief)...
Mylan Generic Accutane Forecast Assumes May/June Launch
Mylan is forecasting the launch of its generic version of Roche's acne therapy Accutane late in the April-June quarter
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”